VERAXA Biotech AG (NASDAQ: VRXA) announced the appointment of Christoph Erkel, Ph.D., as chief scientific officer, effective immediately. Erkel, who previously served as vice president of research and development, will oversee the advancement of the company’s proprietary BiTAC(R) platform technologies, which are designed to develop cancer therapies targeting solid tumors. He succeeds Rick Austin, Ph.D., who will depart after a transition period.
Erkel brings over two decades of experience in antibody therapeutics, antibody engineering, and preclinical development. His prior leadership roles include positions at MorphoSys AG, where he led immuno-oncology programs focused on T-cell engagers. VERAXA stated that his expertise in managing multidisciplinary research programs will be instrumental in expanding the company’s oncology pipeline and advancing BiTAC(R) candidates toward clinical development.
The appointment comes as VERAXA seeks to accelerate its pipeline of bispecific T-cell engagers and antibody-drug conjugates (ADCs) based on its BiTAC platform. The company’s technology originates from scientific breakthroughs at the European Molecular Biology Laboratory (EMBL), a renowned life sciences research institution. With Erkel at the helm of R&D, VERAXA aims to move its candidates from preclinical stages into clinical trials, addressing significant unmet needs in solid tumor oncology.
“We are thrilled to have Christoph take on this expanded role,” said a company spokesperson. “His deep experience in antibody engineering and immuno-oncology will be invaluable as we progress our BiTAC platform toward the clinic.” The company noted that Erkel’s leadership will help streamline the transition from research to development, leveraging his track record in advancing T-cell engager programs.
For more details on the announcement, the full press release is available at https://nnw.fm/cR1RS. Additional information about VERAXA and its news can be found in the company’s newsroom at https://ibn.fm/VRXA.
The BiTAC(R) platform represents a novel approach to engaging T-cells for cancer therapy, potentially offering improved efficacy and safety profiles compared to existing bispecific antibodies. With Erkel’s appointment, VERAXA signals its commitment to advancing this technology into clinical testing, which could have significant implications for patients with solid tumors who currently have limited treatment options.
This article contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to differ materially, as detailed in the company’s SEC filings. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The company undertakes no obligation to update them except as required by law.
